Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community

Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community

September 13, 2007

Newly Independent Radiation Oncology Company Emerges as
Industry Leader with Distinct Focus on Partnership,
Innovation and Integration

    VEENENDAAL, The Netherlands, Sept. 13
/Xinhua-PRNewswire/ -- Nucletron announced today the
successful management buy-out from Delft Instruments,
creating an independent company fully dedicated to
radiation oncology.  Since its inception in 1974, Nucletron
has operated several entities in the field of radiation
oncology throughout the world.  The consolidation of the
various entities into one, focused company further
establishes Nucletron in a leadership role in this rapidly
changing field.  Collaborative partnerships, pioneering
research and development of advanced technological
innovations will enable Nucletron to more effectively
deliver cancer treatment solutions globally and set the
company apart within the industry.

    "The creation of an independent Nucletron is the
result of the company's success in the past two
years," said David Imperiali, chief executive officer
of Nucletron.  "Nucletron has a strong tradition of
innovation in radiotherapy, and the breadth of our
capability positions the company well to continue to make
significant contributions to the treatment of
cancer."

    The previous company, under Delft Instruments, was
created in 1994 by merging Nucletron, the global leader in
brachytherapy solutions, with the Oldelft Simulix(TM) brand
of radiation therapy simulation and imaging technology.
Additionally, in 2003, Nucletron integrated the Helax and
Theratronics treatment planning and management solutions,
from MDS Nordion, into its portfolio to create Oncentra(R)
MasterPlan(TM) and Oncentra(R) Information Management. 

    "Nucletron's ability to restructure itself,
anticipate needs, and incorporate new state-of-the-art
products and services into our solutions suite gives us the
ability to create strong and long-lasting relationships with
our customers and partners," said Jeroen Cammeraat,
chief operating officer of Nucletron.  "The new
corporate structure gives us the flexibility and agility to
continue to develop world-class solutions for our customers
and partners, focused on improving patient care."

    With more than 10 percent of its revenues invested in
research and development, Nucletron continuously seeks
improvement of its existing product range and creation of
new treatment options that improve patients' quality of
care through curative and palliative treatment.  The
company's continued efforts in R&D, both in-house and
through partnerships with leading academic institutions,
have resulted in a strong and unique IP base.  

    Headquartered in The Netherlands, Nucletron delivers
customized solutions to more than 3,000 institutions in
more than 120 countries, equating to global sales of ?120
million ($160 million), with operating profit levels that
rank in the upper quartile of the industry.   Worldwide,
Nucletron has offices in 16 countries, including a
production and R&D facility in The Netherlands, R&D
centers in Uppsala, Sweden and Oslo, Norway and sales,
marketing, service and support operations in Europe, Asia,
Australia and North America. 

    The supervisory board of Nucletron will be chaired by
Rob Westerhof, who has held senior positions in Asia and in
the USA for Philips Medical Systems and Philips Electronics.
 Commenting on the spin-off, Westerhof stated, "I am
excited to join Nucletron's supervisory board.  Being
involved in the medical business for more than 15 years in
various positions throughout the world, I trust that I can
make a contribution. Nucletron represents a strong brand in
the world of oncology and related areas, and there are
excellent opportunities for expanding our market share. I
am looking forward to working with the new management team
and further strengthening Nucletron."

    About Nucletron

    Nucletron is a knowledge-based leader in Radiation
Oncology, working with clinical teams to realize innovative
solutions that improve patient care.  Nucletron strives to
offer the best possible choice of radiation modalities
through integrated products, software and services. 
Critical to the Nucletron philosophy is the establishment
of close working relationships with individual clinical
teams - reconfiguring traditional boundaries between
customer and solution provider.  Many Nucletron employees
have clinical experience delivering oncology care,
providing an in-depth understanding of the complex needs of
clinicians.  The investors in the independent Nucletron
company include AlpInvest Partners, Advent International,
the Nucletron Management and Employees. For more
information, visit http://www.nucletron.com.


    For more information, please contact:

     In North America:
     Danielle Davis 
     Rose Communications 
     Phone: [phone]
     Email: [e-mail]

     In Europe:
     Mark van Braak of Nucletron
     Phone: [phone]
     Email: [e-mail]

     Website: http://www.nucletron.com